David A. Braun

VDJdive and ECLIPSE resolve ambiguous clonotypes in scTCR-seq by improving chain pairing and clone size estimation, enhancing clonal tracking across conditions.

This paper introduces a live tumor fragment platform to assess immunotherapy response in core needle biopsies, showing it can detect T-cell responses and mitigate tissue heterogeneity challenges.

The paper uses patient tumor samples to identify lineage- and context-specific mechanisms of innate immune resistance through perturbational single-cell RNA sequencing.

This paper introduces TIME_ACT, a transcriptomic signature predicting immune checkpoint blockade response across cancers, validated using histopathology and multiple cohorts.

This paper scales large language models for single-cell analysis, improving predictive and generative capabilities and enabling biological discovery through virtual screening.

The paper identifies epigenomic signatures in sarcomatoid renal cell carcinoma (sRCC) that predict response to immune checkpoint inhibitors and are detectable in plasma, enabling non-invasive diagnosis.

This study identifies germline rare variants associated with clear and non-clear cell RCC, accounting for population stratification, and finds distinct risk patterns and somatic associations.

This study identifies three germline variants associated with immune-related adverse events in patients treated with immune checkpoint inhibitors.